We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Microfluidic Device Captures Tumor-Specific Extracellular Vesicles

By LabMedica International staff writers
Posted on 21 Mar 2018
A microfluidic device has been developed that can capture glioblastoma-derived extracellular vesicles, with high specificity, using very small blood samples, which would be useful for pediatric patients.

The microfluidic channels in the device contain a cocktail of antibodies that are specific for molecules found on glioblastoma-derived extracellular vesicles, meaning the vesicles are captured as they pass through the channels.

Scientists at Massachusetts General Hospital (Charlestown, MA, USA) and their colleagues collected blood samples from a total of 13 brain cancer patients and six healthy donors were included in this study. More...
Microfluidic devices consisted of 8-Channel herringbone structures were fabricated using standard photolithography and different strategies were tested for optimal configuration of capture antibodies on the surface of the microfluid device.

Isolated extracellular vesicles (EVs) were quantified using a tunable resistive pulse sensing (TRPS) qNano instrument. EV’s were isolated with immobilized with streptavidin-coated magnetic particles. The cyclic olefin copolymer (COC) The COC microfluidic device allowed direct imaging of captured EVs. Micrographs were captured with an LSM510 confocal microscope equipped with a ×63 Zeiss Plan-APOCHROMAT oil objective. RNA was isolated and quantified. Digital polymerase chain reaction, library preparation for RNA sequencing and RNA sequencing analysis was also performed.

The team reported that the sensitive analytical microfluidic platform (EVHB-Chip) that enables tumor-specific EV-RNA isolation within three hours. Using the EVHB-Chip, They achieved 94% tumor-EV specificity, a limit of detection of 100 EVs per μL, and a 10-fold increase in tumor RNA enrichment in comparison to other methods. This approach allowed for the subsequent release of captured tumor EVs, enabling downstream characterization and functional studies. Processing serum and plasma samples from glioblastoma multiforme (GBM) patients, they detected the mutant Type III epidermal growth factor receptor (EGFRvIII) messenger RNA (mRNA).

Shannon L. Stott, PhD, an Assistant Professor of Medicine and the lead investigator of the study, said, “Our device’s ability to sort tumor-specific extracellular vesicles out from the billions of extracellular vesicles carried through the blood stream may lead to the development of much-needed diagnostic and monitoring tools for this and other hard-to-treat cancers.” The study was published online on January 12, 2018, in the journal Nature Communications.

Related Links:
Massachusetts General Hospital


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.